















































aggregation	 due	 to	 the	 corresponding	 polyglutamine	 (polyQ)	 tract	 in	 proteins	 leading	 to	
neurodegeneration.	 The	mechanism	of	 aggregation	 involves	 primary	 and	 secondary	 nucleation	
steps	and	we	show	how	a	non-canonical	member	of	the	DNAJ-chaperone	family,	DNAJB6,	inhibits	
the	 conversion	 of	 soluble	 polyQ	 peptides	 into	 amyloid	 fibrils	 by	 strongly	 suppressing	 primary	
nucleation.	This	inhibition	is	mediated	by	a	conserved	serine/threonine-rich	region	in	DNAJB6	that	
provides	an	array	of	surface-exposed	hydroxyl	groups	that	can	bind	to	polyQ	peptides	and	disrupt	
the	 formation	 of	 H-bonds	 that	 are	 essential	 for	 the	 stability	 of	 amyloid	 fibrils.	 We	 show	 in	
addition	that	the	early	prevention	of	polyQ	aggregation	by	DNAJB6	also	occurs	in	living	cells	and	























Insights	 into	 the	 mechanism	 by	 which	 DNAJB6,	 a	 member	 of	 the	 DNAJ-family	 of	 molecular	
chaperones,	 inhibits	 early	 steps	 in	 the	 formation	 of	 polyglutamine	 amyloid	 fibrils.	 A	 unique	
serine/threonine	(S/T)-rich	region	 in	DNAJB6	that	exposes	an	array	of	hydroxyl	groups	 is	crucial	
for	 inhibition	of	amyloid	 formation.	Activity	 is	gradually	 lost	 in	S/T-to-A	substitution	variants	of	











In	 trinucleotide	 (CAG)	 repeat	 expansion	 disorders,	 which	 include	 Huntington’s	 disease	 (HD),	
spinocerebellar	 ataxias	 (SCAs)	 and	 spinal	 and	 bulbar	 muscular	 atrophy	 (SBMA),	 proteins	
containing	 polyglutamine	 (polyQ)	 stretches	 promote	 protein	 aggregation	 and	 formation	 of	
pathological	 structures	 such	 as	 amyloid	 fibrils	 and	 their	 precursors	 (Chiti	 and	 Dobson,	 2006;	
Zoghbi	 and	Orr,	 2000).	 The	 length	 of	 the	 polyQ	 expansion	 is	 strongly	 linked	with	 aggregation	
propensity,	 and	 is	 also	 inversely	 correlated	with	 the	 age	 at	 onset	 of	 the	 disease	 (Gusella	 and	
MacDonald,	2000).	These	findings	strongly	suggest	that	aggregate	formation	triggers	disease.	Yet	






al.,	 2011;	 Raspe	 et	 al.,	 2009).	 The	 proteolytic	 parts	 of	 the	 protein	 containing	 the	 polyQ	
expansions	can	either	directly	or	after	further	processing	via	the	proteasome	into	polyQ-peptides	
(Raspe	et	al.,	2009;	Venkatraman	et	al.,	2004),	promote	the	subsequent	aggregation	of	the	full-
length	 polyQ	 proteins	 and	 of	 other	 Q-stretch	 containing	 proteins,	 including	 a	 range	 of	
transcription	factors	(Suhr	et	al.,	2001;	Venkatraman	et	al.,	2004;	Waelter	et	al.,	2001).	Indeed,	
sequestration	within	 these	 aggregates	 of	 essential	 transcription	 factors,	 or	 of	 chaperones	 and	
proteasome	 components	 (Park	 et	 al.,	 2013;	 Raspe	 et	 al.,	 2009),	 appears	 to	 be	 one	 of	 the	 key	
pathogenic	events	that	contribute	to	the	functional	impairment	of	neurons.	
Molecular	chaperones	generally	maintain	protein	homeostasis	 in	cells	 (Hipp	et	al.,	2014).	
Some	 can	 bind	 to	 unfolded	 polypeptides	 and	 assist	 their	 folding	 and	 assembly,	 thereby	
suppressing	non-productive	protein-protein	 interactions	 and	aggregate	 formation	 (Balch	et	 al.,	
2008).	Several	chaperones	are	upregulated	upon	acute	stress	in	a	process	referred	to	as	the	heat	




Aggregate	 formation	 is,	 however,	 not	 always	 observed	 to	 be	 reduced	 under	 such	 conditions	
(Warrick	et	al.,	1998),	and	in	mouse	models	of	polyQ	diseases	the	activation	of	HSR	(Labbadia	et	
al.,	 2011),	 or	 the	 transgenic	 expression	 of	 individual	 chaperones	 such	 as	 HSPA1A	 (Hsp70)	
(Hansson	et	al.,	2003;	Hay	et	al.,	2004)	and	HSPB1	(Hsp27)	(Zourlidou	et	al.,	2007),	has	generally	
not	been	found	to	delay	disease	onset	or	reduce	aggregate	formation.	Moreover,	the	expression	
of	 polyQ	 proteins	 per	 se	 does	 not	 activate	 the	 HSR,	 implying	 that	 the	 protein	 quality	 control	
(PQC)	system	does	not	respond	to	the	presence	of	the	protein	with	the	polyQ	expansion	(Seidel	
et	al.,	2012);	this	finding	may	explain	why	the	canonical	chaperones	have	been	so	disappointingly	
ineffective	 in	 polyQ	 diseases.	 There	 are	 also	 members	 of	 the	 diverse	 families	 of	 molecular	




their	 functional	 states	 and	 non-canonical	 in	 their	mode	 of	 action	 (Kampinga	 and	 Craig,	 2010).	
DNAJB8	(expressed	in	the	testis)	and	DNAJB6	(expressed	in	several	tissues	and	especially	in	the	
brain)	 were	 found	 to	 be	 very	 efficient	 suppressors	 of	 polyQ	 aggregation	 in	 cell	 models,	
irrespective	of	the	protein	context	in	which	these	expansions	reside,	either	huntingtin	exon-1	or	
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a	 full	 length	 ataxin	 3	 or	 the	 androgen	 receptor	 (Hageman	 et	 al.,	 2010).	 Efficient	 inhibition	 of	
aggregation	initiated	by	polyQ	peptides	has	been	observed	to	occur	both	in	cell	free	(Månsson	et	
al.,	2014a)	and	in	cellular	models	(Gillis	et	al.,	2013).	Yet,	the	mode	of	action	for	the	remarkable	
efficiency	of	DNAJB6	as	a	 suppressor	molecule	 is	not	understood,	nor	whether	 it	 translates	 to	
protection	in	vivo.		
Here,	we	have	addressed	 the	 following	key	questions	concerning	 the	mechanism	of	how	
DNAJB6	 can	 inhibit	polyQ	aggregation	 so	efficiently:	How	does	DNAJB6	 influence	aggregation?	
What	features	of	DNAJB6	make	it	so	special	compared	to	other	chaperones?	Is	the	inhibition	of	
polyQ	 aggregation	 by	 DNAJB6	 of	 any	 relevance	 for	 disease	 also	 in	 a	mammalian	 system?	We	
show	that	analysis	of	the	kinetics	of	aggregation	reveals	the	fact	that	DNAJB6	inhibits	early	steps	
in	the	formation	of	amyloid	fibrils,	and	that	the	 inhibition	activity	 is	mediated	by	a	unique	and	
conserved	 serine/threonine	 (S/T)-rich	 region.	 In	 addition,	we	 show	 that	 this	 inhibition	 activity	
translates	 into	 the	 prevention	 of	 neurite	 retraction,	 even	 prior	 to	 formation	 of	 inclusions	 in	







containing	proteins,	we	 studied	 formation	of	amyloid	 fibrils	 from	a	widely	used	6.5	kDa	polyQ	
peptide	 (sequence	 GAMKSFQ45F)	 by	 monitoring	 the	 kinetic	 profiles	 of	 the	 thioflavin	 (ThT)	
fluorescence	 changes	 (Månsson	 et	 al.,	 2014a).	 Identification	 of	 the	microscopic	mechanism	of	
protein	aggregation	from	the	analysis	of	the	corresponding	macroscopic	kinetic	profiles	is	based	
on	 the	 fact	 that	 the	 formation	 of	 amyloid	 fibrils	 is	 the	 consequence	 of	 a	 series	 of	 specific	
processes,	 including	 primary	 nucleation,	 fibril	 elongation,	 fibril	 fragmentation	 and	 secondary	
nucleation,	 all	 of	 which	 are	 associated	with	 individual	 reaction	 rate	 constants.	Moreover,	 the	
time	 evolution	 of	 fibril	 formation	 can	 be	 described	 by	 a	 master	 equation	 that	 includes	 the	
contributions	of	 the	various	 individual	microscopic	processes	 (Arosio	et	al.,	2014;	Cohen	et	al.,	
2011a,	 2011b).	 The	 data	 obtained	 by	 analysis	 of	 the	 kinetics	 of	 the	 aggregation	 reaction	 at	
different	concentrations	of	the	polyQ	peptide	(Fig.	1A)	indicate	that	secondary	nucleation	plays	a	
key	role	 in	polyQ	peptide	aggregation,	and	in	the	generation	of	the	oligomeric	species	that	are	
likely	 to	 be	 the	primary	 agents	 of	 cellular	 toxicity.	Next,	 the	 aggregation	profiles	 of	 the	polyQ	
peptide	in	the	presence	of	DNAJB6	were	analyzed	(Fig.	1B,	C).	The	experimental	measurements	






of	 polyQ	 peptide	 to	 DNAJB6	 monomer	 of	 1:0.1,	 the	 data	 indicate	 that	 the	 rate	 of	 primary	
nucleation	is	reduced	by	a	factor	of	109	(Fig.	1F,	black	bar).	However,	DNAJB6	also	perturbs	the	
secondary	nucleation	process,	even	though	to	a	much	smaller	degree.	Whereas	this	effect	alone	
cannot	well	describe	 its	 full	mechanism	of	 action	 (Fig.	 1C),	 secondary	nucleation	 rates	are	 still	
reduced	by	 a	 factor	 of	 50	 in	 the	presence	of	DNAJB6	 at	 1	 1:0.1	 ratio	 (Fig.	 1G,	 black	 bar).	 The	
effects	on	secondary	nucleation	pathways	are	further	supported	by	additional	analysis	of	seeded	
aggregation	 reaction	 (Fig.	 S1):	 adding	 polyQ	 fibrils	 to	 the	 reaction	 enhances	 monomer	
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aggregation	(Fig	S1A)	and	DNAJB6	can	also	slow	down	these	reactions,	the	magnitude	depending	
on	 the	percentage	of	 seeds	added	 (Fig.	 S1B).	 Including	both	effects	on	primary	and	 secondary	















in	 the	 loss	 of	 anti-aggregation	 activity,	 and	 also	 to	 loss	 of	 HDAC	 binding	 and	 the	 oligomeric	
conformation	found	in	cells	(Hageman	et	al.,	2010),	and	as	isolated	purified	protein	(Månsson	et	
al.,	2014a).	This	conserved	region	in	DNAJB6	contains	many	hydroxyl	groups	in	the	side	chains	of	
the	 S/T-residues.	 Since	 the	 low	molecular	weight	 compound	 EGCG,	 a	 potent	 inhibitor	 of	 fibril	
formation,	 contains	 exposed	 hydroxyl	 groups,	 which	 have	 been	 proposed	 to	 engage	 in	
establishing	intramolecular	hydrogen	bonding	with	polyQ	peptides	(Ehrnhoefer	et	al.,	2006),	and	
hydroxyl	 groups	 in	 conserved	 tyrosine	 residues	 of	 the	 Brichos	 chaperone	 are	 important	 for	
inhibiting	 amyloid	 formation	 (Willander	 et	 al.,	 2012).	 In	 order	 to	 explore	 the	 potential	





DNAJB6	variant	M4	 in	which	 the	entire	S/T-region	 is	deleted	 is	 structurally	perturbed,	and	 the	
oligomeric	conformation	is	lost	(Fig.	S3C)	as	was	previously	seen	in	cells	(Hageman	et	al.,	2010),	





S3E):	 only	 a	 minor	 shift	 in	 the	monomer-oligomer	 equilibrium	was	 found	 when	 compared	 to	
wildtype	DNAJB6.	From	the	ThT	fluoresence	measurements	it	was	evident	that	the	function,	i.e	
the	aggregation	 inhibition	 capacity	of	 the	wildtype	DNAJB6,	declined	declined	as	 a	 function	of	
the	number	of	S/T-to-A	substitutions	and	was	almost	completely	 lost	when	all	18	S/T	 residues	
are	substituted	with	A	residues	(Fig.	1E,	Fig	S5).	Detailed	analysis	of	the	aggregation	kinetics	(Fig	
1F,	G)	 revealed	 that	 the	 S/T-to-A	 substitutions	 affected	 the	 ability	 to	 inhibit	 both	primary	 and	
secondary	steps	in	the	aggregation	reactions.		
Structural	modeling	of	DNAJB6	(Fig.	S4)	suggested	that	the	array	of	18	side-chain	hydroxyl	
groups	 are	 exposed	 on	 one	 face	 of	 the	 DNAJB6	monomer	 (Fig.	 1H,	 highlighted	 in	 pink).	 That	





(Fig.	1I).	Quantitation	of	 the	 immunofluorescence	data	 indicate	 that	 the	mutational	variants	of	
DNAJB6	without	the	S/T-rich	region	were	to	a	smaller	extent	binding	and	captured	into	the	polyQ	
fibrils	during	their	formation,	compared	to	wildtype	DNAJB6	(Fig.	1J).	Taken	together,	the	data	in	





compared	 its	 effects	 on	 the	 aggregation	 of	 intracellular	 polyQ	 and	 assessed	 how	 this	 is	
accelerated	 by	 an	 extracellular	 addition	 to	 the	 media	 of	 polyQ	 peptides	 in	 aggregated	 and	




formed	no	aggregates	 spontaneously	within	48	h	 (Fig.	2B-D),	but	aggregation	was	observed	 to	
occur	during	3-48	h	following	extracellular	addition	of	polyQ	peptides	in	aggregated	and	fibrillar	
form	 (Fig.	 2A,	 2C-E),	 referred	 to	 as	 [Q45	 seed]extra	 (Fig.	 2C-E).	 DNAJB6	 almost	 completely	
suppressed	aggregation	initiated	intracellularly	by	eGFP-tagged	exon-1	of	the	huntingtin	protein	
with	 a	 pathogenic	 Q	 stretch	 ([Htt-Q74-eGFP]intra)	 without	 such	 extracellular	 addition	 of	 seeds	
(Fig.	 2D,	 lower	 panel),	 whereas	 DNAJB6	 was	 found	 to	 only	 slightly	 delay	 aggregation	 of	









crowded	 environment	 of	 living	 cells,	 we	 expressed	 exon-1	 of	 the	 huntingtin	 protein	 with	 an	
expanded	 polyQ	 stretch	 (Htt-Q119-eYFP)	 in	 HEK293	 cells	 and	 compared	 the	 results	 with	 or	
without	co-expression	of	wildtype	DNAJB6	or	the	S/T-substitution	variants.	These	data	showed,	
in	 close	 similarity	 to	 the	 observations	 in	 the	 in	 vitro	 experiments	 with	 purified	 mutational	
variants	of	the	DNAJB6	protein	(Fig.	1),	that	the	anti-aggregation	capacity	of	DNAJB6	was	found	
to	decline	with	the	number	of	S/T	substitutions	in	DNAJB6	also	in	cells,	by	counting	the	fraction	






compared	 the	 results	with	or	without	 co-expression	of	DNAJB6.	Analysis	 of	 polyQ	aggregation	
using	 the	 filter	 trap	assay	 (Fig.	4A,	B)	or	by	measuring	 the	 formation	of	high	molecular	weight	





the	 neurites	 (Fig.	 4C,	 Fig.	 S6C).	 Cells	 with	 Htt-Q119-eYFP	 inclusions	 (IF-detectable	 aggregates)	
had	fewer	processes	(Fig.	4D).	Cells	expressing	Htt-Q23-GFP	(a	non-pathogenic	polyQ	stretch,	in	
contrast	to	the	pathogenic	expanded	polyQ	stretch	in	Htt-Q119-eYFP)	were	unaffected	(data	not	
shown),	 demonstrating	 that	 the	 observed	 effects	 were	 indeed	 due	 to	 the	 expanded	 polyQ	
stretch.	In	cells	with	Htt-Q119-eYFP	inclusions,	there	were	on	average	2.0	processes/cell	without	
DNAJB6;	 in	 the	 few	 cells	 showing	 inclusions	 when	 co-expressing	 DNAJB6	 this	 number	 was	
significantly	 higher	 (4.1	 processes/cell).	 Importantly,	 DNAJB6	 co-expression	 increased	 the	
number	 of	 processes	 also	 in	 cells	 without	 detectable	 aggregates	 (2.1	 processes/cell	 without	
DNAJB6;	5.7	processes/cell	with	DNAJB6)(Fig.	4C,	D).	In	addition,	FRAP	analysis	(Fig.	S7)	revealed	
that	the	mobility	of	the	otherwise	diffusely	distributed	Htt-Q119-eYFP,	in	areas	within	the	cytosol	








To	 confirm	 early	 interaction	 of	 DNAJB6	 with	 soluble,	 non-aggregated	 polyQ	 species	 we	








J-domain	 which	 is	 crucial	 for	 DNAJ-Hsp70	 functional	 interactions	 (Kampinga	 and	 Craig,	 2010).	
Indeed,	DNAJB6	can	interact	with	the	Hsp70	family	member	HSPA1A	in	cells,	as	revealed	by	co-
immunoprecipitation	 analyses	 (Fig.	 5B),	 whereas	 a	 mutant	 carrying	 a	 substitution	 in	 the	
conserved	 HPD	 domain	 (H31Q:	 converting	 this	 motif	 from	 HPD	 to	 QPD)	 completely	 loses	 its	
ability	 to	 interact	 with	 HSPA1A.	 In	 contrast,	 the	 M3	 mutational	 variant	 with	 18	 S/T	 >	 A	
substitutions	still	fully	retained	is	ability	to	interact	with	HSPA1A	(Fig.	5B),	further	supporting	the	




mixture	 with	 DNAJB6	 (Månsson	 et	 al.,	 2014a).	 However,	 given	 the	 very	 efficient	 protection	
against	polyQ	aggregation	at	extremely	low	stoichiometry,	we	hypothesized	that	the	capacity	of	






the	 already	 impaired	 M2	 mutational	 variant	 of	 DNAJB6,	 showed	 an	 almost	 complete	 loss	 of	
inhibitory	 activity,	 whereas	 the	 QPD-mutation	 in	 the	 wildtype	 DNAJB6	 still	 inhibited	 polyQ	
aggregation	to	75%	(Fig.	5C-H).	This	result	implies	that	DNAJB6	is	a	bona-fide	DNAJ	protein	that	
in	 principle	 has	 the	 capability	 to	 bind	 to	 and	 collaborate	 with	 Hsp70,	 although	 such	 Hsp70	
interaction	is	required	only	under	conditions	where	the	DNAJB6	capacity	is	 limited.	Under	such	






chaperone	 activity.	 The	 ability	 of	 DNAJB6	 to	 inhibit	 aggregation	 of	 polyQ	 containing	 proteins	
relies	on	direct	 interaction	with	the	substrate,	the	polyQ	stretch	 itself,	an	ability	that	canonical	





Brain-specific	 DNAJB6	 expression	 reduces	 aggregation	 and	 delays	 disease	 onset	 in	 a	
polyglutamine	mouse	model.	
To	 study	whether	or	not	 the	highly	protective	effects	of	DNAJB6	observed	 in	 vitro	 and	 in	 cells	
also	 translate	 into	 neuro-protection	 in	 vivo,	 we	 generated	 transgenic	 mice	 that	 express	 the	
human	DNAJB6	under	control	of	the	brain-specific	nestin	promotor	(Fig.	6A),	with	no	significant	
expression	 in	 other	 tissues	 (Fig.	 6B,	 C).	 DNAJB6	 transgenic	 mice	 were	 born	 in	 the	 expected	
Mendelian	ratios	and	did	not	show	any	overt	phenotype.	The	expression	of	the	human	DNAJB6	
transgene	 did	 not	 affect	 the	 expression	 of	 the	 endogenous	mouse	 DNAJB6	 nor	 of	 any	 of	 the	
other	DNAJs	analyzed	(Fig.	S8).	In	addition,	the	HSPA1A	(the	stress-regulated	Hsp70)	levels	were	
unaltered	 in	 brain	 and	 muscle	 lysates	 from	 the	 transgenic	 mice	 (Fig.	 S9)	 showing	 that	
overexpression	of	DNAJB6	does	not	induce	a	general	stress	response.	
Next,	 the	DNAJB6	transgenic	mice	were	crossed	with	R6/2	mice	expressing	exon-1	of	the	
human	 huntingtin	 gene,	 containing	 201	 ±	 1	 CAG	 repeats:	 this	 R6/2	 model	 exhibits	 the	 most	
rapidly	 progressing	 features	of	 polyglutamine	pathogenicity	 in	 any	mouse	model	 and	 captures	
several	key	aspects	of	human	disease,	 including	early	onset	motor	dysfunction	associated	with	
the	 generation	 of	 protein	 aggregates	 in	 the	 brain,	 and	 a	 substantial	 reduction	 in	 lifespan	
(Mangiarini	et	al.,	1996;	Menalled	et	al.,	2009).	Whole	brain	lysates	from	R6/2	mice	(referred	to	




the	 DNAJB6	 transgene	 (Fig.	 6D,E).	 Moreover,	 Immunohistochemical	 analysis	 on	 paraffin-
embedded	 brain	 sections	 revealed	 an	 age-dependent	 increase	 in	 the	 formation	 of	 nuclear	
inclusions	 in	 the	striatum	of	 the	HTT	mice	 (Fig.	6D,	E)	but	not	 in	 the	WT	or	DNAJB6	transgenic	
mice	 (Fig.	 S10).	 Importantly,	 formation	 of	 inclusions	 in	 the	 brain	 was	 greatly	 reduced	 in	 the	
double	transgenic	HTT/JB6	mice	at	all	time-points	recorded	(Fig.	6D,	E).	Biochemical	detection	of	
aggregates	 (as	 high	molecular	 weight	 smears)	 in	 total	 brain	 lysates	 also	 showed	 reduction	 of	




We	next	 investigated	the	effect	of	this	reduction	 in	aggregate	 load	 in	the	brain	on	motor	
(dysfunction)	symptoms.	In	agreement	with	earlier	data	(Mangiarini	et	al.,	1996;	Menalled	et	al.,	
2009),	 the	 HTT	 mice	 showed	 an	 early	 decline	 in	 rotarod	 performance,	 which	 progressively	
deteriorated	 with	 age.	 In	 the	 HTT/JB6	 double	 transgenic	 mice,	 however,	 this	 decline	 was	








related	 progressive	 muscle	 atrophy	 has	 been	 reported	 to	 be	 a	 significant	 contributor	 to	 the	
impaired	motor	ability	 and	early	death	 in	 the	R6/2	model	 (Orth	et	 al.,	 2003;	Ribchester	et	 al.,	
2004;	 Sathasivam	 et	 al.,	 1999).	 We	 confirmed	 that	 aggregates	 were	 indeed	 present	 in	 the	
muscles	of	R6/2	mice	but,	 consistent	with	 the	brain	 specific	DNAJB6	expression,	 the	extent	of	
aggregation	in	quadriceps	skeletal	muscle	in	the	HTT/JB6	mice	was	found	to	be	similar	to	that	in	
the	 HTT	 mice	 (Fig.	 S11B).	 In	 addition,	 wasting	 effects,	 indicated	 by	 muscle	 weight	 loss,	 were	
found	 to	 be	 similar	 in	 both	 HTT	 and	 HTT/JB6	 mice	 (Fig.	 S11C).	 Since	 muscle	 waste	 likely	




Our	present	 findings	have	 identified	a	conserved	and	unique	S/T-rich	region	 in	DNAJB6,	a	non-
canonical	member	of	the	DNAJ-family	of	molecular	chaperones,	as	a	key	element	in	preventing	
polyQ	 aggregation	 and	 amyloid	 formation.	We	 show	how	 the	 capability	 of	 DNAJB6	 to	 directly	







understanding	 the	 nature	 and	 rates	 of	 the	 specific	 microscopic	 steps	 in	 the	 mechanism	 of	
aggregation	(Arosio	et	al.,	2014;	Cohen	et	al.,	2015).	In	particular,	the	rate	of	primary	nucleation	
was	 found	to	be	significantly	 reduced	 in	 the	presence	of	DNAJB6	 (Fig.	1),	which	 is	expected	to	
delay	 the	 formation	of	aggregates	 in	vivo	and	to	reduce	the	population	of	 the	toxic	oligomers,	
particularly	at	early	time	points	(Arosio	et	al.,	2014;	Cohen	et	al.,	2015).	The	cellular	data	(Fig.	2-
5)	and	the	data	acquired	from	experiments	with	the	transgenic	mice	(Fig.	6,7)	are	in	agreement	
with	 this	 prediction,	 providing	 evidence	 that,	 in	 this	 polyQ	 system	 at	 least,	 the	 aggregation	
process	observed	in	vitro	is	analogous	to	that	generating	the	toxicity	observed	in	vivo.	Inhibition	






been	 found	 to	 result	 in	 a	 loss	 of	 function	 in	 aggregation	 inhibition	 (Hageman	 et	 al.,	 2010).	
However,	since	deletion	of	the	entire	S/T-rich	region	also	affected	DNAJB6	structure,	oligomeric	
conformation	 and	 HDAC	 binding,	 it	 was	 unclear	 as	 to	whether	 or	 not	 this	 stretch	was	 in	 fact	
directly	involved	in	suppression	of	polyQ	aggregation.	The	results	described	here	show	that	S/T-
to-A	 substitution	 does	 not	 affect	 the	 secondary	 structure	 and	 oligomeric	 conformation	 of	
DNAJB6,	 and	 demonstrate	 that	 the	 extremely	 efficient	 inhibition	 by	 DNAJB6	 of	 primary	
nucleation	 is	 totally	dependent	on	 this	 region	of	DNAJB6,	and	of	 the	array	of	18	hydroxyl	 side	
chains	 that	 is	 exposed	 asymmetrically	 on	one	 side	 of	 the	DNAJB6	monomer	 structure	 (Fig.	 1).	






Our	data	also	provide	an	explanation	 for	 the	 findings	 that	DNAJB6	 (and	DNAJB8)	are	 the	most	
potent	 suppressors	 of	 polyQ	 aggregation	 within	 the	 human	 chaperonome	 (Hageman	 et	 al.,	
2010).	The	protective	effects	of	DNAJB6	in	the	aggressive	R6/2	polyQ	mouse	model	(Figs.	6,	7)	is	
the	 largest	 reported	 protection	 so	 far	 for	 any	 study	 involving	 the	 over-expression	 of	 a	 single	
human	 chaperone.	 Indeed,	 HSPA1A	 (Hsp70)	 and	 HSPB1	 (Hsp27)	 have	 been	 found	 to	 be	
ineffective	 in	 this	model	 (Hansson	et	 al.,	 2003;	Hay	et	 al.,	 2004;	 Zourlidou	et	 al.,	 2007),	whilst	
DNAJB2,	 a	 DNAJ	 protein	 that	 is	 related	 to	 DNAJB6	 but	 lacks	 the	 S/T	 stretch,	 leads	 to	modest	
effects	on	disease	onset	(Labbadia	et	al.,	2012).	The	high	potency	of	DNAJB6	can	be	attributed	to	
its	 direct	 interaction	 with	 the	 amyloid	 forming	 polyQ	 expansions,	 inhibiting	 primary	 and	 also	
secondary	nucleation	(Fig.	1).	Other	chaperones	like	HSPA1A	(Hsp70)	or	DNAJB1	(Hsp40)	cannot,	
however,	 act	 in	 this	 way	 but	 may	 interact	 with	 polyQ	 inclusions	 after	 they	 are	 formed,	 for	
example	by	binding	 to	exposed	hydrophobic	groups	of	 the	aggregated	polyQ	proteins.	 Indeed,	










The	 finding	 that,	 in	 cells,	 DNAJB6	 and	 DNAJB8	 not	 only	 delay	 aggregation	 of	 polyQ	
containing	 huntingtin,	 but	 also	 of	 polyQ	 containing	 ataxin-3	 and	 the	 androgen	 receptor	
(Hageman	et	al.,	 2010),	 further	 supports	 the	conclusion	 that	 its	action	must	 involve	 the	polyQ	
stretch	itself	in	a	context-independent,	generic	manner,	consistent	with	its	ability	to	chaperone	
pure	polyQ	peptides	 (this	 report,	Månsson	et	al.,	2014a).	For	 this	 to	happen,	 it	 is	 important	to	
note	that	the	polyQ	stretch	in	the	full-length	polyQ	proteins	usually	is	not	exposed	and	that	the	
full-length	polyQ	proteins	are	not	intrinsically	misfolded,	which	is	another	reason	why	canonical	
chaperones	 may	 not	 recognize	 them	 prior	 to	 aggregation,	 and	 thus	 are	 not	 very	 effective	 in	
suppressing	these	diseases.	In	line	with	this	conclusion,	expression	of	full	length	polyQ	proteins	
does	 not	 trigger	 the	 heat	 shock	 response	 (Hageman	 et	 al.,	 2010;	 Seidel	 et	 al.,	 2012)	 and	 the	
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steady	 state	 expression	 levels	 of	 the	 expanded	 and	 non-expanded	 alleles	 are	 identical	 in	 cells	
from	polyQ	patients	 (Koch	et	 al.,	 2011;	 Zijlstra	et	 al.,	 2010),	 strongly	 indicating	 that	 the	polyQ	
expansion	does	render	the	protein	a	target	for	accelerated	degradation	as	seen,	for	example,	for	
misfolded	 disease-associated	 proteins	 such	 as	 the	 mutational	 variants	 of	 SOD1	 that	 are	
responsible	for	ALS	(Crippa	et	al.,	2010),	or	some	of	the	CFTR	mutants	that	are	associated	with	
cystic	 fibrosis	 (Villella	 et	 al.,	 2013).	 For	 the	 polyQ	 expansion	 to	 become	 exposed	 and	 initiate	
aggregation,	 several	 lines	 of	 evidence	 have	 revealed	 that	 the	 full	 length	 proteins	 have	 to	 be	
shortened,	either	by	protease	cleavage	(Graham	et	al.,	2006)	or	via	alternative	splicing	(Ramani	
et	 al.,	 2015;	 Sathasivam	 et	 al.,	 2013),	 or	 need	 to	 undergo	 conformational	 changes	 such	 that	
flanking	sequences	open	up	or	align	the	polyQ	stretch	for	β-hairpin-mediated	nucleation	(Hoop	
et	 al.,	 2014;	 Kar	 et	 al.,	 2013;	 Orr	 et	 al.,	 2010;	 Sivanandam	 et	 al.,	 2011).	 In	 addition,	 or	
alternatively,	polyQ	peptides	can	be	generated	upon	proteasomal	degradation	that,	in	a	polyQ-
length	dependent	manner,	may	aggregate	and	act	as	seeds	for	fibril	formation	(Gillis	et	al.,	2013;	
Raspe	 et	 al.,	 2009).	 At	 this	 stage	 DNAJB6,	 but	 not	 canonical	 chaperones,	 would	 be	 able	 to	
prevent	such	seeds	from	being	formed.	
Whereas	prevention	of	polyQ	aggregation	by	DNAJB6	has	previously	been	suggested	to	be	
independent	of	 its	ability	 to	work	within	 the	context	of	 the	Hsp70	machinery	 (Hageman	et	al.,	
2010),	our	current	data	demonstrate	that	this	idea	has	to	be	revised.	This	activity	is	not	yet	fully	
saturated	under	 the	conditions	used	previously	 (Hageman	et	al.,	2010),	a	situation	 that	 results	
from	the	extremely	efficient	substrate-binding	capacity	of	DNAJB6	at	sub	stoichiometric	 ratios.	
Our	 current	 data	 with	 the	 QPD-M2	 double	 mutant	 of	 DNAJB6	 (Fig.	 5)	 demonstrate	 that	 the	
additional	QPD	mutation	 in	 the	M2	mutational	 variant	of	DNAJB6,	 already	 compromised	 in	 its	




degradation	 via	 Hsp70,	 at	 the	 same	 time	 releasing	 DNAJB6	 for	 preventing	 new	 primary	
nucleation	reactions.	The	Hsp70-independent	ability	of	DNAJB6	to	delay	polyQ	aggregation	in	a	
cell	 free	system	(Månsson	et	al.,	2014a)	 is	not	 inconsistent	with	such	a	model,	as	 the	released	
seeds	would	not	be	degraded	and	thus	would	not	change	the	substrate-to-chaperone	ratio.	How	
the	 substrates	 released	 from	 DNAJB6	 by	 HSP70	 are	 processed	 (e.g.	 by	 hand-over	 to	 either	




DNAJB6	 is	expressed	ubiquitously,	not	 just	 in	 the	brain,	and	DNAJB6	orthologs	are	 found	 in	all	
metazoans	analyzed	so	 far	 (Hageman	et	al.,	2010).	Yet,	 its	precise	 function	under	physiological	
conditions	remains	to	be	elucidated.	Besides	playing	a	potential	role	in	suppressing	unwanted	or	
uncontrolled	amyloid	formation,	some	data	suggest	that	DNAJB6	is	important	during	(excessive)	
protein	 degradation;	 for	 example,	 DNAJB6	 has	 been	 suggested	 to	 play	 a	 role	 during	 keratin	
degradation	(Izawa	et	al.,	2000;	Watson	et	al.,	2007),	which	may	explain	why	DNAJB6	knockout	
mutant	mice	die	due	to	 failures	of	chorioallantoic	 fusion	 (Hunter	et	al.,	1999).	 In	 line	with	 this	
view,	expression	network	analysis	 (Fig.	 S12)	 reveals	 that	DNA	expression	 is	 strongly	associated	
with	 catabolic	 processes.	 One	 speculative	 possibility	 is	 that	 DNAJB6	may	 play	 a	more	 general	






et	al.,	2014),	 supporting	 the	proposal	 that	 it	has	an	 important	anti-aggregation	role	 in	muscles	
under	physiological	conditions.	
	 Specific	overexpression	of	DNAJB6	 in	 the	brain	has	not	been	 found	 to	have	deleterious	
phenotypic	 effects,	 at	 least	 in	 the	 mouse	 model	 used	 here,	 suggesting	 that	 it	 could	 be	 a	
potentially	 safe	 therapeutic	 target	 in	polyQ	diseases.	 Furthermore,	 in	 line	with	 the	absence	of	
effects	on	the	general	chaperone	network	 in	the	brain	(Figs.	S8,	9),	 the	tissue-specific	effect	of	
DNAJB6	 implies	 that	 its	upregulation	does	not	 lead	to	cell-non-autonomous	effects	of	 the	type	
that	have	been	suggested	to	occur,	 for	example,	with	 the	HSR-regulator	DNAJB1	 (Popiel	et	al.,	
2012).	This	observation,	and	the	fact	that	DNAJB6	does	not	require	a	simultaneous	upregulation	
of	 Hsp70	 for	 its	 chaperone	 activity,	 is	 likely	 to	 be	 a	major	 advantage	 because	 altering	 Hsp70	
expression	levels	has	been	associated	with	an	increased	risk	of	malignancies	(Dai	et	al.,	2007).	In	




peptides,	 observed	 in	 the	present	 study,	 appears	 to	be	unique	 amongst	 the	DNAJ	 chaperones	
investigated	so	far.	DNAJB6	might,	therefore,	also	play	an	important	role	in	the	context	of	other	
human	 disorders,	 in	 addition	 to	 those	 associated	 with	 polyQ	 aggregation,	 where	 amyloid	
formation	is	an	important	factor.	Such	disorders	include	Alzheimer’s	disease,	the	most	common	
cause	of	age-related	dementia,	that	is	initiated	by	Aβ	peptides	(Knowles	et	al.,	2014),	and	type	2	
diabetes,	 in	which	 the	cascade	 initiating	aggregation	 involves	 IAPP	peptides,	a	major	 secretory	
product	of	β-cells	(Westermark	et	al.,	2011).	Indeed,	we	have	recently	found	that	DNAJB6	is	able	
to	 interact	 with,	 and	 delay	 fibril	 formation	 by,	 the	 Aβ42	 peptide	 (Månsson	 et	 al.,	 2014b). In	
conclusion,	molecular	species	that	are	able	to	 interfere	with	protein	aggregation	are	of	utmost	
importance	 for	 understanding	 the	 role	 of	 amyloid	 formation	 in	 biology	 and	 disease.	 Further	
insights	into	the	mechanism	by	which	DNAJB6	inhibits	this	process	will	help	to	understand	both	
the	nature	of	 the	aggregation	process	 itself	 and	of	 its	 inhibition,	and	may	 thereby	 serve	as	an	






DNAJB6	protein.	The	 residue	numbering	 refers	 to	 the	 amino	 acid	 sequence	of	 human	DNAJB6	
isoform	b	(UniProt	KB	accession	number	O75190-2).	DNAJB6	was	recombinantly	expressed	with	
an	N-terminal	tag	containing	six	histidines	and	a	tobacco	etch	virus	(TEV)	protease	cleavage	site	
(tag	 sequence	MHHHHHHGKPIPNPLLGLDSTENLYFQGIDPFT).	 After	 TEV-cleavage	 and	 removal	 of	
the	 His-tag,	 the	 amino	 acid	 residues	 GIDPFT	 remain	 at	 the	 N-terminal	 end	 of	 the	 DNAJB6	
protein).	 Substitution	 mutants	 were	 generated	 with	 6,	 13	 or	 18	 S/T-to-A	 substitutions	 in	 the	
conserved	S/T-rich	region	and	designated	M1,	M2,	and	M3	and	one	deletion	mutant	(Δ132-183),	
with	 21	 S/T	 residues	 and	 in	 total	 35	 residues	 deleted,	 and	 designated	M4.	 Expression	 of	 the	
DNAJB6	 protein	 and	 its	 mutational	 variants	 was	 performed	 at	 the	 Lund	 Protein	 Production	
Platform,	 Lund	 University,	 Sweden	 (http://www.lu.se/lp3).	 Purification	 and	 characterization	 of	
the	 proteins	 by	 native	 electrophoresis	 and	 CD	 spectroscopy	 was	 performed	 as	 previously	
described	 (Månsson	 et	 al.,	 2014a,	 2014b).	 Size	 exclusion	 chromatography	was	 performed	 at	 a	
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flow	rate	of	0.5	ml/min	on	a	Superdex	200	Increase	10/300	GL	column	(GE	Healthcare,	Uppsala,	
Sweden)	 equilibrated	 with	 20	 mM	 sodium	 phosphate	 buffer	 pH	 8	 and	 150	 mM	 NaCl.	 	 The	
preparation	of	 the	polyQ	peptide	used	here	 for	 in	 vitro	 studies	has	been	described	previously	







Saint-Germain-en-Laye,	 France),	 equilibrated	 in	 20	mM	Tris–HCl,	 pH	 7.5;	 100	mM	KCl;	 20	mM	
imidazole;	10	%	glycerol	and	1	mM	DTT,	and	an	imidazole	gradient	(20–500	mM)	was	applied	and	
the	His-tagged	MBP-TEV-Q45	was	eluted	at	200	mM	imidazole,	and	then	loaded	on	the	UnoQ6	











mM	 KH2PO4)	 and	 transferred	 to	 a	 cellulose	 acetate	 membrane	 filter	 (pore	 size	 0.2	 μm,	 GE	
Healthcare,	Uppsala,	Sweden)	on	a	suction	device.	The	membrane	 filter	was	washed,	 to	 retain	
only	polyQ	in	fibril	 form,	twice	with	PBS	supplemented	with	1	%	SDS	and	once	with	PBS	alone,	
after	which	it	was	blocked	by	incubation	with	blocking	buffer	(LI-COR,	Cambridge,	UK)	for	1h	at	
RT,	 then	 incubated	 with	 blocking	 buffer	 containing	 1:1000	 polyclonal	 rabbit	 anti	 DNAJB6	









Assay	 for	 DNAJB6	 suppression	 of	 polyQ	 aggregation.	 PolyQ	 fibril	 formation	was	 analyzed	 by	
Thioflavin	T	(ThT)	fluorescence;	15	μM	MBP-TEV-Q45	was	mixed	with	DNAJB6	or	its	mutational	
variants	 in	 two	 distinct	 molar	 ratios	 (1:0.1	 and	 1:0.01)	 of	 MBP-TEV-Q45	 to	 DNAJB6	 and	 its	
mutational	 variants	 in	 buffer	 (55.9	 mM	 NaPB,	 143.5	 mM	 NaCl	 and	 1.35	 mM	 KCl,	 pH	 8.0),	
supplemented	with	10	μM	ThT	 for	detection	of	 fibril	 formation	and	1.5	ng/ml	TEV	protease	to	
initiate	 the	 reaction.	 Samples	 were	 prepared	 on	 ice	 and	 80	 µl	 aliquots	 were	 transferred	 to	
microplate	wells	(Corning®	96	well	plates,	half-area	black/clear	bottom	polystyrene,	nonbinding	
surface,	 Corning	 Incorporated	 Life	 Sciences,	 Acton,	 USA)	 in	 triplicate.	 ThT	 fluorescence	 was	









profiles	were	 fitted	by	 integrated	 rate	 laws	 for	 nucleation	 and	 growth	 as	 previously	 described	
(Arosio	et	al.,	2014;	Cohen	et	al.,	2011a,	2011b),	considering	rate	constants	in	the	absence	and	
presence	of	different	concentrations	of	DNAJB6	and	the	mutational	variants,	where	kn,	k+	and	k2	




the	 details	 of	 the	 microscopic	 mechanism	 underlying	 the	 inhibition	 of	 polyQ	 	 aggregation	 by	
DNAJB6,	 we	 applied	 a	 recently	 developed	 chemical	 kinetics	 platform.	 To	 this	 effect,	 the	
experimental	 kinetic	 data	 in	 vitro	 were	 analysed	 by	 using	 a	 kinetic	 model	 that	 considers	 the	
processes	of	primary	nucleation,	elongation	and	secondary	nucleation.	The	time	evolution	of	the	





where	 the	 kinetic	 parameters	 B±,	 C±,	 and	 κ	 are	 functions	 of	 the	 two	 combinations	 of	 the	
microscopic	 rate	 constants	 k+k2	 and	 k+kn,	 where	 kn,	 k+	 and	 k2	 are	 the	 primary	 nucleation,	
elongation	and	 secondary	nucleation	 rate	 constants,	 respectively.	 The	microscopic	aggregation	
mechanism	of	the	Q45	peptide	 in	the	absence	of	the	chaperone	was	 identified	by	applying	Eq.	
{1}	to	globally	fit	the	reaction	profiles	at	different	concentrations	of	Q45.	The	experimental	data	
were	 taken	 from	 (Månsson	 et	 al.,	 2014a)	 and	 the	 reaction	 orders	 of	 primary	 and	 secondary	
nucleation	 were	 fixed	 as	 2	 based	 on	 the	 scaling	 of	 the	 halftimes	 with	 initial	 peptide	
concentrations.	This	global	analysis	 indicated	that	the	aggregation	of	the	polyQ	peptides	under	
the	 conditions	 explored	 in	 the	 present	 study	 is	 dominated	 by	 secondary	 nucleation,	 although	
primary	 nucleation	 occurs	 to	 generate	 the	 initial	 species	 that	 subsequently	 proliferate	 by	







to	 the	Robetta	 server	 (http://robetta.bakerlab.org,	 (Song	et	 al.,	 2013).	 Intra-	 and	 inter-domain	
crosslinks	 identified	by	CXMS	were	used	as	distance	 constraints	 to	 filter	 the	 structural	models	
and	 select	 that	with	 the	 best	 fit.	 Crosslinking	 experiments	were	 performed	 in	 20	mM	 sodium	


































(disulfosuccinimidylglutarate,	 also	 abbreviated	 as	 BS2G	 for	 bis[sulfosuccinimidyl]glutarate)	 and	
BS3	 (bis[sulfosuccinimidyl]suberate),	 are	 amine-reactive,	 water	 soluble,	 homobifunctional	
protein	 crosslinkers	 yielding	 7.7	 Å	 and	 11.4	 Å	 long	 spacer	 arms	 between	 lysine	 residues,	 and	
were	 purchased	 from	 Creative	 Molecules	 Inc.	 (Victoria,	 Canada).	 The	 DNAJB6	 protein	
concentration	 was	 1	 mg/ml.	 The	 crosslinking	 agents	 were	 dissolved	 in	 distilled	 water	 to	 a	




mM.	 The	 samples	 were	 then	 subjected	 to	 denaturing	 gel	 electrophoresis	 performed	 using	
precast	4–12	%	NuPAGE®	Bis–Tris	Gels	(Life	Technologies	Europe	BV,	Stockholm,	Sweden)	in	MES	









source	 (Proxeon	 Biosystems,	 Odense,	 Denmark).	 The	 chromatographic	 separation	 was	
performed	at	400C	on	a	15	cm	(75	μm	i.d.)	EASY-Spray	column	packed	with	3	μm	resin	(Proxeon	
Biosystems,	 Odense,	 Denmark).	 The	 nanoHPLC	 intelligent	 flow	 control	 gradient	 was	 5–20%	
solvent	B	(0.1%	(v/v)	FA,	100%	(v/v)	acetonitrile	in	water)	in	solvent	A	(0.1%	(v/v)	FA	in	water)	for	
60	min,	and	then	20%-40%	for	30	min	followed	with	an	increase	to	90%	for	5	min.	A	flow	rate	of	
300	 nl/min	 was	 used	 through	 the	 whole	 gradient.	 An	 MS	 scan	 (usually	 350–2000	 m/z)	 was	




ion	 injection	 time,	 2.5	 m/z	 isolation	 width,	 10	 ms	 activation	 time	 at	 35	 normalized	 collision	




per	 scan	with	 the	 software	MassAI	 (version	August	 2014;	http://www.massai.dk;	 ((Peng	et	 al.,	
2014;	 Rasmussen	 et	 al.,	 2011).	 The	 identification	 of	 crosslinks	 was	 made	 with	 the	 following	
search	 settings:	 Fragmentation	 mode:	 CID,	 10	 ppm	 MS	 accuracy,	 0.04	 Da	 MS/MS	 accuracy,	











cells	was	 induced	using	1%	NECA	 (Sigma)	 and	0.1%	 IBMX	 (Sigma).	 Cells	were	 transfected	with	




described	 earlier	 (Hageman	 et	 al.,	 2010).	 For	 immune-staining,	 differentiated	 cells	 were	
additionally	stained	for	βIII-tubulin	to	visualize	neurites.		
	
Cell	 and	 tissue	 extracts	 and	 sample	 preparation	 for	 western	 blotting.	 HEK293	 cells	 were	
prepared	and	treated	as	described	previously	(Hageman	et	al.,	2010).	For	extracellular	addition	
of	 polyQ	 peptide	 in	 aggregated	 and	 fibrillar	 forms	 polyQ	 peptide,	 the	 peptides	 K2Q30K2	 and		
K2Q45K2	were	generated	as	described	before	(Ren	et	al.,	2009).	The	peptides	were	added	to	the	
culture	medium	at	 a	 concentration	of	 1	µM	one	day	 after	 transfection	with	 the	plasmids	Htt-
Q23-GFP	or	Htt-Q47-GFP	 and	DNAJB6-V5.	 After	 the	 indicated	 time	 following	 peptide	 addition,	
the	cells	were	washed	with	PBS	and	scraped	in	FTA-buffer	(10	mM	Tris-Cl	pH8.0,	150	mM	NaCl)	+	
2%	 SDS	 and	 sonicated.	 Seeding	 of	 intracellular	 expressed	 Htt-Q23-GFP	 or	 Htt-Q74-GFP	
aggregation	in	HEK293	cells	was	induced	by	addition	of	extracellular	preformed	Q45	fibrils	(1µM)	
one	 day	 after	 transfection	 with	 the	 plasmids	 encoding	 Htt-Q23-GFP	 or	 Htt-Q74-GFP	 with	 or	
without	 plasmids	 encoding	 DNAJB6-V5.	 Preformed	 Q45	 fibrils	 were	 obtained	 by	 incubating	
soluble	Q45	 (40	µM)	 in	20	mM	HEPES,	pH	7.5;	150	mM	NaCl	and	10%	glycerol,	at	37°C	without	
shaking.	Full	assembly	into	fibrils	was	achieved	within	5h	as	assessed	by	SDS-PAGE	analysis	and	
electron	 microscopy.	 To	 reduce	 fibrils	 length	 heterogeneity	 and	 bundling,	 preassembled	 Q45	
fibrils	were	sonicated	for	20	min	on	ice	in	2-mL	Eppendorf	tubes	in	a	VialTweeter	powered	by	an	
ultrasonic	processor	UIS250v	(250	watts,	2.4	kHz;	Hielscher	Ultrasonic,	Teltow,	Germany)	set	at	
75%	 amplitude,	 0.5	 s	 pulses.	 Transmission	 electron	micrographs	 of	 fibrillar	Q45	 adsorbed	 onto	
carbon-coated	200	mesh	grids	and	negatively	 stained	with	1%	uranyl	acetate	 in	distilled	water	
for	 1	 min	 were	 acquired	 using	 JEOL	 1400	 transmission	 electron	 microscope	 operated	 at	 an	
excitation	 voltage	 of	 80kV	 and	 equipped	with	 a	 Gatan	Orius	 CDD	 Camera	 (Gatan)	 (Ren	 et	 al.,	
2009).	
Filter	trap	samples	were	prepared	as	described	before	(Hageman	et	al.,	2010).	For	mouse	tissue	
extracts	 and	 aggregate	 detection,	 the	 tissues	were	 snap	 frozen	 in	 liquid	 nitrogen	 immediately	
after	 dissection	 and	 homogenized	 (with	 a	 pellet	 pestle	 for	 brain	 tissue	 and	 a	 bead	 beater	 for	
muscle	tissue)	in	RIPA	buffer	with	NaCl	(150	mM),	igepal	cholate	(1%),	deoxycholate	(0.5%),	SDS	




the	 DC	 protein	 assay	 (BioRad,	 Veenendaal,	 Netherlands)	 and	 prepared	 in	 SDS-PAGE	 loading	
buffer	and	heated	for	5	min	at	100oC.	Equal	amounts	of	protein	(5	µg	for	NG108	cell	extracts	and	
50	 µg	 for	 tissue	 extract)	 were	 loaded	 on	 8%	 (Htt	 detection)	 and	 12.5%	 SDS-PAGE	 gels.	 The	
proteins	were	transferred	onto	nitrocellulose	membranes	and	probed	with	the	following	primary	
antibodies:	 anti-GFP	 (JL-8	 Clontech,	 Leusden,	 NL);	 anti-V5	 (Invitrogen,	 CA,	 USA);	 anti-DNAJB6	
(Abnova,	Walnut,	CA,	USA)	and	anti-GAPDH	(Fitzgerald	Industries	International,	Acton,	MA,	USA);	
anti-Htt	S829	(generated	in	the	Bates	laboratory,	London,	UK),	and	subsequently	incubated	with	




















Immunoprecipitation	 protocols.	 For	 the	 polyQ-DNAJB6	 immunoprecipitation,	 HEK293T	 cells	
were	co-transfected	with	pcDNA5/FRT/TO	V5-DNAJB6b	WT	and	an	empty	pcDNA5/FRT/TO	mRFP	
vector	(0.9µg	each),	or	0.1	µg	of	Htt-Q119-YFP	and	0.9	µg	of	either	pcDNA5/FRT/TO	V5-DNAJB6b	




resuspended	 in	 500	 µl	 PBS	 with	 the	 cross	 linker	 3,3ʹ-dithiodipropionic	 acid	 di(N-
hydroxysuccinimide	ester)	(1	mM	final	concentration,	Sigma-Aldrich)	and	incubated	on	ice	for	30	




mM	 DTT	 and	 complete	 EDTA-free	 protease	 inhibitor	 cocktail)	 were	 used	 to	 homogenize	 the	
pellets,	which	were	passed	7	 times	 through	a	26G	needle.	Cells	were	 spun	 for	15	min,	14.000	
rpm	at	4oC,	the	supernatant	fractions	were	transferred	to	new	tubes	and	30	µl	were	collected	
for	 input	 measurement	 before	 addition	 of	 25	 µl	 of	 GFP-Trap®	 magnetic	 beads	 (Chromotek,	
Planegg,	Germany).	Extracts	were	 incubated	at	4oC	for	2	h	under	gentle	agitation,	 followed	by	
one	wash	with	500	µl	of	lysis	buffer	without	DTT,	one	wash	with	500	µl	of	lysis	buffer	with	300	
mM	NaCl	 and	 four	washes	with	 lysis	 buffer	 (with	DTT	and	150	mM	NaCl)	 on	 a	magnetic	 rack.	
Beads	were	resuspended	in	25	µl	of	2X	Laemli	buffer	with	10%	2-mercaptoethanol	and	boiled	for	






XhoI	 site	 of	 the	 Z/EG	 expression	 vector,	 and	 verified	 by	 sequence	 analysis.	 A	 ScaI-linearized	
vector	 was	 transfected	 into	 ES	 cells	 by	 electroporation	 and	 G418-resistant	 colonies	 with	 high	
expression	levels	of	Flag-DNAJB6	were	selected	as	previously	described	(van	Ree	et	al.,	2011).	ES	
	 18	
cells	 were	 karyotyped	 and	 injected	 into	 C57BL/6	 blastocysts	 to	 generate	 chimeric	 animals.	
Chimeric	males	 were	 used	 for	 breeding	 and	 offspring	 were	 screened	 for	 the	 presence	 of	 the	
transgene	by	PCR.	Mice	were	backcrossed	to	C57BL/6	for	at	least	6	generations.	To	excise	the	β-
geo-stop	 cassette	 in	 neurons,	 DNAJB6	 transgenic	mice	were	 bred	 to	Nesting-Cre	mice	 (B6.Cg-




of	 Groningen	 Ethical	 Committee	 for	 Animal	 Experiments,	 which	 adheres	 to	 the	 principles	 and	
guidelines	 established	 by	 the	 European	 Convention	 for	 the	 Protection	 of	 Laboratory	 Animals.	
Experiments	were	 carried	 out	 on	R6/2	mice	 and	DNAJB6	 transgenic	mice	 that	were	 housed	 in	
cages	2-3	mice/cage)	under	conditions	of	standard	cage	enrichment	and	with	ad	libitum	access	
to	food	and	water.	Hemizygous	R6/2	mice	were	bred	by	backcrossing	R6/2	HD	males	to	(CBA	x	
C57Bl/6)	 F1	 females	 (B6CBAF1/OlaHsd,	 Harlan	 Olac).	 The	 genotyping	 and	 CAG	 repeat	
measurements	were	 carried	out	 as	described	previously	 (Mangiarini	 et	 al.,	 1996)	with	primers	
R6/2	 fwd/rev	&	HDAC4	 fwd/rev	used	 for	 genotyping	R6/2	mice	 and	40256	 fwd–40261	 rev	 for	
CAG	 repeat	 sizing	 (Supplementary	 Table	 I).	 The	 presence	 of	 the	 DNAJB6	 transgene	 was	
confirmed	 by	 using	 primer	 pairs	 amplifying	 the	 human	DNAJB6	 transgene,	 NEO	 and	 CRE.	 The	
sequences	of	all	the	primers	used	in	this	study	are	listed	in	Supplementary	Table	I.	
	
Quantitative	PCR.	Total	RNA	was	extracted	 from	 tissue	 samples	by	 the	Trizol	method.	1	μg	of	
total	 RNA	 was	 transcribed	 using	 M-MLV	 reverse	 transcriptase	 (Invitrogen,	 Thermo	 Fisher	
Scientific	 Inc.,	Waltham,	MA,	 USA).	 The	 cDNA	 synthesis	 was	 performed	 with	 oligo	 (dT)	 12-18	
(Invitrogen,	 Thermo	 Fisher	 Scientific	 Inc.,	 Waltham,	 MA,	 USA).	 Relative	 changes	 in	 transcript	
levels	were	determined	on	 the	 Icycler	 (Bio-Rad,	Hercules,	CA,	USA)	using	SYBR	green	supermix	
(Bio-Rad,	 Hercules,	 CA,	 USA).	 Calculations	 were	 done	 using	 the	 comparative	 CT	 method	
according	to	User	Bulletin	2	(Applied	Biosystems,	Foster	City,	CA,	USA).	For	each	set	of	primers,	
the	 PCR	 efficiency	 was	 determined	 standard	 curves	 with	 different	 concentration	 of	 primers.	
Primer	sequences	used	in	this	study	are	listed	in	Supplementary	Table	I.	
	
Immunohistochemistry.	 Dissected	 mouse	 brains	 and	 muscles	 were	 fixed	 in	 4%	 buffered	











a	 gap	of	 4	weeks	between	 the	 recordings	 (in	order	 to	 avoid	 learning),	 two	 cohorts	 of	 animals	
were	 used.	 The	 recordings	 from	 4,	 8,	 12,	 16	weeks	 served	 as	 one	 cohort	 and	 from	 6,	 10,	 14	
weeks	as	another	cohort.	At	each	time	point,	the	mice	were	tested	on	three	consecutive	days,	
for	three	trials	per	day.	The	data	are	plotted	as	an	average	of	all	the	trials	for	each	day.	Statistical	
























V.K.,	H.H.K,	B.vd.S,	 S.B,	C.E,	 and	C.M	designed	and	conceived	 the	experiments.	V.K.,	C.M.,	 and	
E.M.	performed	 the	experiments.	M.vd.Z.,	M.A.W.H.v.W.,	N.J.K.,	 and	R.v.C,.	 provided	 technical	








Hersenstichting	 Grant	 to	 S.B.	 (project	 no.	 F2013(1)-52).	 The	 in	 vitro	 aggregation	 work	 was	
facilitated	 by	 recombinant	 expression	 of	 the	 DNAJB6	 protein	 performed	 at	 the	 Lund	 Protein	
Production	Platform,	Lund	University,	Sweden	(http://www.lu.se/lp3)	and	was	funded	by	the	LU	
Research	 School	 for	 Pharmaceutical	 Science,	 the	Magnus	 Bergwalls	 Stiftelse	 and	 the	 Crafoord	
Foundation	 (CE),	 the	 European	 Research	 Council,	 the	 Swedish	 Research	 Council	 and	 the	
Nanometer	 Structure	 Consortium	 (SL).	 PA	 acknowledges	 the	 support	 of	 the	 European	
Community	 for	 a	Marie	Curie	 Fellowship	 for	 career	development.	 TPJK	and	CMD	acknowledge	
financial	 support	 from	 the	BBSRC,	 the	Frances	and	August	Newman	Foundation,	 the	European	
Research	Council	and	the	Wellcome	Trust.	Marije	Been,	Sophie	M.	Post	and	Jeanette	F.	Brunsting	
are	thanked	for	their	help	with	the	cellular	experiments	using	the	DNAJB6	mutants,	and	Martha	














Balch,	 W.E.,	 Morimoto,	 R.I.,	 Dillin,	 A.,	 and	 Kelly,	 J.W.	 (2008).	 Adapting	 proteostasis	 for	 disease	
intervention.	Science	319,	916–919.	
Carra,	 S.,	 Seguin,	 S.J.,	 and	 Landry,	 J.	 (2008).	 HspB8	 and	 Bag3:	 a	 new	 chaperone	 complex	 targeting	
misfolded	proteins	to	macroautophagy.	Autophagy	4,	237–239.	





Chou,	 A.-H.,	 Yeh,	 T.-H.,	 Ouyang,	 P.,	 Chen,	 Y.-L.,	 Chen,	 S.-Y.,	 and	 Wang,	 H.-L.	 (2008).	 Polyglutamine-






















L.,	Wellington,	 C.L.,	 Salvesen,	 G.S.,	 et	 al.	 (1999).	 Kennedy’s	 disease:	 caspase	 cleavage	 of	 the	 androgen	
receptor	is	a	crucial	event	in	cytotoxicity.	J.	Neurochem.	72,	185–195.	






Graham,	 R.K.,	 Deng,	 Y.,	 Slow,	 E.J.,	 Haigh,	 B.,	 Bissada,	 N.,	 Lu,	 G.,	 Pearson,	 J.,	 Shehadeh,	 J.,	 Bertram,	 L.,	
Murphy,	 Z.,	 et	 al.	 (2006).	 Cleavage	 at	 the	 caspase-6	 site	 is	 required	 for	 neuronal	 dysfunction	 and	
degeneration	due	to	mutant	huntingtin.	Cell	125,	1179–1191.	






Hut,	 H.M.J.,	 Lubsen,	 N.H.,	 and	 Kampinga,	 H.H.	 (2010).	 A	 DNAJB	 chaperone	 subfamily	 with	 HDAC-
dependent	activities	suppresses	toxic	protein	aggregation.	Mol.	Cell	37,	355–369.	
Hansson,	O.,	Nylandsted,	J.,	Castilho,	R.F.,	Leist,	M.,	Jäättelä,	M.,	and	Brundin,	P.	(2003).	Overexpression	






B.,	 and	 Bates,	 G.P.	 (2004).	 Progressive	 decrease	 in	 chaperone	 protein	 levels	 in	 a	 mouse	 model	 of	





Hockly,	 E.,	 Richon,	 V.M.,	Woodman,	 B.,	 Smith,	 D.L.,	 Zhou,	 X.,	 Rosa,	 E.,	 Sathasivam,	 K.,	 Ghazi-Noori,	 S.,	
Mahal,	A.,	Lowden,	P.A.S.,	et	al.	(2003).	Suberoylanilide	hydroxamic	acid,	a	histone	deacetylase	inhibitor,	
ameliorates	motor	deficits	 in	 a	mouse	model	of	Huntington’s	disease.	Proc.	Natl.	Acad.	 Sci.	U.S.A.	100,	
2041–2046.	
Hoop,	 C.L.,	 Lin,	 H.-K.,	 Kar,	 K.,	 Hou,	 Z.,	 Poirier,	 M.A.,	 Wetzel,	 R.,	 and	 van	 der	 Wel,	 P.C.A.	 (2014).	










a	DnaJ/Hsp40	 family	 protein,	 as	 a	 keratin	 8/18	 filament	 regulatory	 protein.	 J.	 Biol.	 Chem.	275,	 34521–
34527.	
Kampinga,	 H.H.,	 and	 Craig,	 E.A.	 (2010).	 The	 HSP70	 chaperone	 machinery:	 J	 proteins	 as	 drivers	 of	
functional	specificity.	Nat.	Rev.	Mol.	Cell	Biol.	11,	579–592.	
Kar,	K.,	Hoop,	C.L.,	Drombosky,	K.W.,	Baker,	M.A.,	Kodali,	R.,	Arduini,	I.,	van	der	Wel,	P.C.A.,	Horne,	W.S.,	
and	Wetzel,	 R.	 (2013).	 β-hairpin-mediated	 nucleation	 of	 polyglutamine	 amyloid	 formation.	 J.	Mol.	 Biol.	
425,	1183–1197.	






S.,	 Frentzel,	 S.,	 Luthi-Carter,	 R.,	 et	 al.	 (2011).	 Altered	 chromatin	 architecture	 underlies	 progressive	
impairment	of	the	heat	shock	response	in	mouse	models	of	Huntington	disease.	J.	Clin.	Invest.	121,	3306–
3319.	
Labbadia,	 J.,	Novoselov,	S.S.,	Bett,	 J.S.,	Weiss,	A.,	Paganetti,	P.,	Bates,	G.P.,	and	Cheetham,	M.E.	 (2012).	
Suppression	of	protein	aggregation	by	chaperone	modification	of	high	molecular	weight	complexes.	Brain	
135,	1180–1196.	





Månsson,	 C.,	 Kakkar,	 V.,	 Monsellier,	 E.,	 Sourigues,	 Y.,	 Härmark,	 J.,	 Kampinga,	 H.H.,	 Melki,	 R.,	 and	
Emanuelsson,	C.	(2014a).	DNAJB6	is	a	peptide-binding	chaperone	which	can	suppress	amyloid	fibrillation	
of	polyglutamine	peptides	at	substoichiometric	molar	ratios.	Cell	Stress	Chaperones	19,	227–239.	
Månsson,	 C.,	 Arosio,	 P.,	 Hussein,	 R.,	 Kampinga,	 H.H.,	 Hashem,	 R.M.,	 Boelens,	 W.C.,	 Dobson,	 C.M.,	
Knowles,	T.P.J.,	 Linse,	S.,	and	Emanuelsson,	C.	 (2014b).	 Interaction	of	 the	molecular	chaperone	DNAJB6	
with	 growing	 amyloid-beta	 42	 (Aβ42)	 aggregates	 leads	 to	 sub-stoichiometric	 inhibition	 of	 amyloid	
formation.	J.	Biol.	Chem.	289,	31066–31076.	
	 23	
Menalled,	 L.,	 El-Khodor,	 B.F.,	 Patry,	 M.,	 Suárez-Fariñas,	 M.,	 Orenstein,	 S.J.,	 Zahasky,	 B.,	 Leahy,	 C.,	
Wheeler,	V.,	Yang,	X.W.,	MacDonald,	M.,	et	al.	 (2009).	Systematic	behavioral	evaluation	of	Huntington’s	
disease	transgenic	and	knock-in	mouse	models.	Neurobiol.	Dis.	35,	319–336.	
Neef,	 D.W.,	 Turski,	 M.L.,	 and	 Thiele,	 D.J.	 (2010).	Modulation	 of	 heat	 shock	 transcription	 factor	 1	 as	 a	
therapeutic	target	for	small	molecule	intervention	in	neurodegenerative	disease.	PLoS	Biol.	8,	e1000291.	
Orr,	C.R.,	Montie,	H.L.,	 Liu,	Y.,	Bolzoni,	E.,	 Jenkins,	S.C.,	Wilson,	E.M.,	 Joseph,	 J.D.,	McDonnell,	D.P.,	and	
Merry,	D.E.	 (2010).	An	 interdomain	 interaction	of	 the	androgen	 receptor	 is	 required	 for	 its	aggregation	
and	toxicity	in	spinal	and	bulbar	muscular	atrophy.	J.	Biol.	Chem.	285,	35567–35577.	
Orth,	 M.,	 Cooper,	 J.M.,	 Bates,	 G.P.,	 and	 Schapira,	 A.H.V.	 (2003).	 Inclusion	 formation	 in	 Huntington’s	
disease	R6/2	mouse	muscle	cultures.	J.	Neurochem.	87,	1–6.	























Ren,	 P.-H.,	 Lauckner,	 J.E.,	 Kachirskaia,	 I.,	 Heuser,	 J.E.,	 Melki,	 R.,	 and	 Kopito,	 R.R.	 (2009).	 Cytoplasmic	
penetration	and	persistent	 infection	of	mammalian	cells	by	polyglutamine	aggregates.	Nat.	Cell	Biol.	11,	
219–225.	
Ribchester,	 R.R.,	 Thomson,	 D.,	Wood,	 N.I.,	 Hinks,	 T.,	 Gillingwater,	 T.H.,	Wishart,	 T.M.,	 Court,	 F.A.,	 and	
Morton,	 A.J.	 (2004).	 Progressive	 abnormalities	 in	 skeletal	 muscle	 and	 neuromuscular	 junctions	 of	
transgenic	mice	expressing	the	Huntington’s	disease	mutation.	Eur.	J.	Neurosci.	20,	3092–3114.	
	 24	
Sarparanta,	 J.,	 Jonson,	 P.H.,	 Golzio,	 C.,	 Sandell,	 S.,	 Luque,	 H.,	 Screen,	 M.,	 McDonald,	 K.,	 Stajich,	 J.M.,	









Kampinga,	 H.H.,	 and	 den	 Dunnen,	W.F.A.	 (2012).	 Cellular	 protein	 quality	 control	 and	 the	 evolution	 of	
aggregates	in	spinocerebellar	ataxia	type	3	(SCA3).	Neuropathol.	Appl.	Neurobiol.	38,	548–558.	
Sivanandam,	V.N.,	Jayaraman,	M.,	Hoop,	C.L.,	Kodali,	R.,	Wetzel,	R.,	and	van	der	Wel,	P.C.A.	(2011).	The	
aggregation-enhancing	huntingtin	N-terminus	 is	 helical	 in	 amyloid	 fibrils.	 J.	 Am.	Chem.	 Soc.	133,	 4558–
4566.	
Song,	 Y.,	DiMaio,	 F.,	Wang,	R.Y.-R.,	 Kim,	D.,	Miles,	 C.,	 Brunette,	 T.,	 Thompson,	 J.,	 and	Baker,	D.	 (2013).	
High-resolution	comparative	modeling	with	RosettaCM.	Structure	21,	1735–1742.	
Suarez-Cedeno,	 G.,	 Winder,	 T.,	 and	 Milone,	 M.	 (2014).	 DNAJB6	 myopathy:	 a	 vacuolar	 myopathy	 with	
childhood	onset.	Muscle	Nerve	49,	607–610.	
Suhr,	 S.T.,	 Senut,	 M.C.,	 Whitelegge,	 J.P.,	 Faull,	 K.F.,	 Cuizon,	 D.B.,	 and	 Gage,	 F.H.	 (2001).	 Identities	 of	





Villella,	 V.R.,	 Esposito,	 S.,	 Bruscia,	 E.M.,	 Maiuri,	 M.C.,	 Raia,	 V.,	 Kroemer,	 G.,	 and	 Maiuri,	 L.	 (2013).	








(1998).	 Expanded	 polyglutamine	 protein	 forms	 nuclear	 inclusions	 and	 causes	 neural	 degeneration	 in	
Drosophila.	Cell	93,	939–949.	
Warrick,	J.M.,	Chan,	H.Y.,	Gray-Board,	G.L.,	Chai,	Y.,	Paulson,	H.L.,	and	Bonini,	N.M.	(1999).	Suppression	of	








Willander,	 H.,	 Presto,	 J.,	 Askarieh,	 G.,	 Biverstål,	 H.,	 Frohm,	 B.,	 Knight,	 S.D.,	 Johansson,	 J.,	 and	 Linse,	 S.	





Zoghbi,	H.Y.,	 and	Orr,	H.T.	 (2000).	Glutamine	 repeats	 and	neurodegeneration.	Annu.	Rev.	Neurosci.	23,	
217–247.	
Zourlidou,	 A.,	 Gidalevitz,	 T.,	 Kristiansen,	M.,	 Landles,	 C.,	Woodman,	 B.,	Wells,	 D.J.,	 Latchman,	 D.S.,	 de	
Belleroche,	J.,	Tabrizi,	S.J.,	Morimoto,	R.I.,	et	al.	(2007).	Hsp27	overexpression	in	the	R6/2	mouse	model	of	





























Legends to the Figures 
Figure	 1:	 Aggregation	 suppression	
mechanism	of	DNAJB6	and	 its	mutational	
variants	 showing	 that	 the	 S/T-rich	 region	
is	a	key	structural	 feature	for	 interactions	
with	 polyQ	 nuclei	 and	 inhibition	 of	
primary	 nucleation	 events.	 (A)	 Kinetic	
profiles	 of	 the	 concentration-dependent	
aggregation	 of	 the	 polyQ	 peptide	 at	
concentrations	 of	 10,	 12.8,	 16	 and	 20	 μM	
monitored	by	ThT	fluorescence.	Continuous	
lines	 represent	 global	 fitting	 of	 the	
integrated	 rate	 laws	 to	 the	data	 according	
to	the	equations	described	in	the	Methods	
section.	The	 inset	shows	the	scaling	of	 the	




μM	 polyQ	 peptide	 in	 the	 absence	 (black)	
and	 presence	 of	 DNAJB6	 (green)	 at	 molar	
ratios	 of	 polyQ:DNAJB6	 of	 1:0.01	 or	 1:0.1;	
the	thin	line	represents	the	fit	of	the	kinetic	
profiles	 according	 to	 Eq.	 {1}	 where	 only	
primary	nucleation	pathways	are	specifically	inhibited	(compare	to	(C)).	(C)	Kinetic	profiles	as	in	








M3	 (orange),	 and	 M4	 (blue)	 at	 molar	 ratios	 of	 polyQ	 to	 DNAJB6	 of	 1:0.01	 and	 1:0.1.	 The	
continuous	lines	represent	fits	of	the	integrated	rate	laws	to	the	data	in	which	inhibition	of	both	
primary	 and	 secondary	 nucleation	 events	 has	 been	 considered	 simultaneously.	 (F,	 G)	 The	
decreases	 in	 the	 rates	 of	 primary	 nucleation	 and	 secondary	 nucleation,	 respectively,	
corresponding	 to	 the	 reaction	 profiles	 in	 (E)	 for	WT	 DNAJB6	 and	 for	 the	M1-M4	 variants,	 all	
normalized	to	the	values	in	the	absence	of	chaperone.	The	fluorescence	data	used	for	all	kinetic	
analyses	 are	 presented	 in	 Fig.	 S5.	 (H)	 Structural	 model	 of	 a	 DNAJB6	monomer,	 generated	 as	
described	in	Fig.	S4,	showing	the	conserved	serine	(S)	and	threonine	(T)	residues	(pink)	exposed	
on	one	side	of	the	DNAJB6	structure.	(I)	The	amount	of	DNAJB6	and	mutational	variants	M1-M4	
of	 DNAJB6	 binding	 to	 and	 captured	 in	 polyQ	 fibrils	 trapped	 on	 filter	 and	 probed	 by	
immunofluorescence	(starting	concentrations	15	µM	polyQ	peptide;	upper	row	1.5	µM	DNAJB6	






HEK293	 cells	 expressing	 Htt-Q23-eGFP	 or	 Htt-Q74-eGFP	 intracellularly,	 with	 or	 without	 V5-




DAPI	 staining	 is	 shown	 in	 blue.	 (C)	 Western	 blots	 of	 the	 same	 cell	 extracts	 as	 in	 panel	 (B).	
Nitrocellulose	membranes	were	probed	with	the	antibodies	indicated.	(D)	Filter	trap	assay	of	the	
same	 cell	 extracts	 as	 in	panel	 (A),	 taken	at	 the	 indicated	 time	points	 after	 the	 addition	of	 the	
[Q45	seeds]extra.	 Three	 serial	 five-fold	dilutions	were	 loaded	onto	cellulose-acetate	membranes	
and	probed	with	anti-GFP	antibodies	to	detect	aggregation	of	the	 intracellularly	expressed	Htt-
Q23-eGFPintra	 or	Htt-Q74-eGFPintra.	 As	 a	 control,	 [Q45	 seeds]extra	were	directly	 added	 after	 lysis	
(post	 lysis)	 and	 showed	 no	 aggregates.	 Cells	 expressing	 Htt-Q74-eGFPintra	 show	 the	 effective	








Figure	 3:	 Effects	 of	 mutations	 in	 the	 S/T-rich	 region	 of	 DNAJB6	 on	 its	 ability	 to	 prevent	




were	 analyzed	 24	 h	 after	 transfection.	 (A)	 Representative	 immunofluorescent	 pictures	 of	 cells		
transfected	 with	 HttQ119-eYFP	 without	 (C)	 or	 with	 the	 wildtype	 (WT)	 or	 the	 various	 DNAJB6	
mutational	variants	(M1-M4).	(B)	Western	blot	of	cell	extracts.	Nitrocellulose	membranes	were	
probed	with	the	antibodies	indicated,	showing	expression	of	the	wild	type	DNAJB6	(WT)	and	the	
M1-M4	mutational	 variants	 using	 an	 anti-V5	 antibody.	 Soluble	 (sol)	 and	 aggregated	Htt-Q119-
eYFP	(stack)	(anti-GFP)	are	also	depicted.	GAPDH	is	provided	as	a	loading	control.	(C)	Serial	five-
fold	dilutions	of	the	same	extracts	as	in	panel	B	were	loaded	onto	cellulose-acetate	membranes	
and	 probed	with	 an	 anti-GFP	 antibody	 to	 detect	 aggregation	 Htt-Q119-eYFP.	 (D)	 Quantitative	
analysis	 of	 the	 images	 in	 panel	 A,	 expressing	 the	 fraction	 of	 cells	 containing	 inclusions	 (2	
experiments,	 each	 scored	 by	 at	 least	 3	 independent	 observers	 and	 then	 averaged).	 (E)	 The	
amount	of	high	molecular	weight	aggregated	(HMW)	polyQ	proteins	 in	panel	B	relative	to	cells	







Figure	 4:	 DNAJB6	 suppresses	 the	 formation	 of	 polyQ	 aggregates	 and	 the	 effect	 of	 polyQ	
expression	 on	 neurite	 formation	 even	 before	 histologically	 visible	 aggregation	 in	 neuronal	
cells.	Differentiated	NG108	cells	were	transfected	with	exon-1	Htt-Q119-eYFP	(Htt-Q119)	with	or	
without	 V5-DNAJB6	 or	 the	 V5-tagged	 DNAJB6	 M3	 variant	 with	 18	 S/T-to-A	 substitutions.	 (A)	
Serial	 five-fold	 dilutions	 of	 the	 cell	 extracts	 in	 SDS-buffer	 were	 loaded	 onto	 cellulose-acetate	
membranes	and	probed	with	an	anti-GFP	antibody	to	detect	aggregation	Htt-Q119-eYFP	and	(B)	
quantified	by	densitometry	(mean	+	SD	of	2	experiments).	(C)	Representative	confocal	images	of	
differentiated	 NG108	 cells	 co-transfected	 with	 Htt-Q119-eYFP	 (green)	 and	 DNAJB6	 with	
additional	staining	of	β-III	tubulin	(red)	and	DAPI	(blue).	(D)	Individual	cells	(approx.	60	cells	per	
condition)	 were	 manually	 counted	 to	 identify	 neurite	 (dendritic)	 processes.	 Cells	 with	 and	






Figure	 5:	 Effects	 of	 an	 HPD	mutation	
on	 the	 ability	 of	 DNAJB6	 to	 prevent	
aggregation	 of	 polyQ	 in	 cells.	 	 (A)	
HEK293T	 cells	 were	 co-transfected	
with	 Htt-Q119-YFP	 constructs	 with	
either	 an	 empty	 vector	 or	 with	 V5-
DNAJB6b	 WT,	 V5-DNAJB6b	 H31Q	 or	
V5-DNAJB6b	 M3	 constructs.	 Cell	
lysates	 were	 treated	 with	 a	 chemical	
cross-linker	 and	 cross-linked	 material	
(input)	 was	 precipitated	 using	 GFP-
Trap	 magnetic	 beads	 (IP:GFP)	 and	
analysed	 by	 westerns	 blotting.	 	 (B)	
Same	 as	 A,	 but	 using	 GFP-tagged	
HSPA1A.	 (C-F)	 HEK293	 cells	 were	
transfected	with	exon-1	Htt-Q119eYFP	
(Htt-Q119)	 without	 (C,	 black)	 or	 with	
the	 wildtype	 V5-DNAJB6	 (WT-HPD,	
green	 solid),	 DNAJB6	with	 a	mutation	
in	 the	HPD	motif	of	 the	 J-domain	that	
disrupts	 its	 interaction	 with	 Hsp70	
(WT-QPD,	 green	 open)	 or	 with	 the	
DNAJB6	 mutational	 variant	 with	 13	
S/T-to-A	 substitutions	 in	 the	 S/T-rich	
region,	 either	 alone	 (M2-HDP,	
turquoise	 solid)	 or	 combined	 with	 a	
mutation	 in	 the	 J-domain	 (M2-QDP,	
turquoise	 open).	 Samples	 were	
analyzed	 24	 h	 after	 transfection.	 (C)	
Western	blot	of	extracts	from	cells	co-
transfected	 with	 exon-1	 Htt-Q119-
eYFP	 (Htt-Q119)	 and	 the	 indicated	
DNAJB6	 variants.	 Nitrocellulose	
membranes	 were	 probed	 with	 the	
antibodies	 indicated,	 showing	 expression	 of	 the	 different	 DNAJB6	 variants	 using	 an	 anti-V5	
antibody,	 soluble	 (sol)	 and	 aggregated	 Htt-Q119-eYFP	 (stack)	 depicted	 using	 an	 anti-GFP	
antibody	and	an	anti-GAPDH	antibody	provided	as	loading	control.	(D)	Serial	five-fold	dilutions	of	
the	same	extracts	as	in	panel	B	were	loaded	on	cellulose-acetate	membranes	and	probed	with	an	
anti-GFP	 antibody	 to	 detect	 aggregated	Htt-Q119-eYFP.	 (E)	 Representative	 immunofluorescent	
pictures	of	cells	transfected	with	HttQ119-eYFP	without	or	with	the	various	DNAJB6	constructs.	
(F)	Quantitative	analysis	of	the	images	like	in	panel	D,	expressing	the	fraction	of	cells	containing	
inclusions	 from	 4	 experiments,	 each	 scored	 by	 at	 least	 3	 independent	 observers	 and	 then	
averaged	 (mean	 ±	 sem).	 (G)	 The	 amount	 of	 high	molecular	 weight	 aggregated	 (HMW)	 polyQ	









for	 specific	 expression	of	DNAJB6	 in	 the	brains	 of	 the	 animals.	 (B)	mRNA	 levels	 of	 the	human	
DNAJB6	 transcript	 relative	 to	 GAPDH	 from	 a	 range	 of	 tissues	 from	 both	 DNAJB6	 transgenic	
(TgDNAJB6:	 green	 bar)	 and	 wild	 type	 (WT:	 black	 bar)	 animals.	 (C)	 Level	 of	 hDNAJB6	 protein	
expression	 in	 the	 brain,	 liver,	 and	 kidney	 in	 two	 TgDNAJB6	 mice	 and	 one	 WT	 mouse.	 (D)	
Huntingtin	 aggregation	 in	 whole	 brain	 lysates	 was	 found	 to	 be	 reduced	 in	 HTT/JB6	 double	
transgenic	mice	compared	to	HTT	mice	at	all	time	points.	The	S829	antibody	was	used	to	detect	
both	HTT	aggregates	 (agg:	 in	stacking	gel)	and	soluble	HTT	(sol).	 (E)	Relative	 levels	of	 insoluble	
HTT	were	plotted	using	GAPDH	as	a	loading	control	and	setting	values	for	the	HTT	mice	at	100%	
(±	sem)	for	each	time-point	(n=3	for	each	group).	The	statistical	significance	was	analysed	using	




animals	 per	 group;	 for	 each	 sample,	 30-40	 nuclei	 were	 counted	 for	 HTT	 aggregates.	 The	




Control	wildtype	mice	 (WT:	 bleu),	DNAJB6	 transgenic	mice	 (JB6:	 red),	 R6/2	mice	 (HTT:	 black)	 and	R6/2	
mice	x	DNAJB5	mice	(HTT/JB6:	green)	were	analyzed	at	the	indicated	time	points	for:	(A)	Performance	on	
a	 rorarod,	 where	 the	 latency	 time	 that	 each	 animal	 stayed	 on	 the	 rotating	 rod	 before	 falling	 was	
monitored	in	3	trials	per	day	for	3	consecutive	days	for	each	group.	The	mean	±	sem	values	of	the	three	
trials	on	each	day	are	plotted.	Data	were	tested	for	normality	by	using	Komogorov-Smirnov	normality	test	
and	was	compared	using	 two-way	ANOVA	 followed	by	a	Holm-Sidak	Post-hoc	 test.	Data	was	extremely	
significant	for	HTT	versus	HTT/JB6	at	12	wks	of	age	(****p<0.0001).	No	statistical	differences	were	found	
between	control	groups	(WT	and	JB6).	(B)	Hind	 limb	clasping	and	 (C)	 full	body	clasping	scored	between	
HTT	 and	 HTT/JB6	 group.	 Chi-Square	 test	 for	 contingency	 was	 performed	 representing	 *p<0.05,	
**p<0.005,	 ***p<0.001	 significance.	 (D)	 Kaplan-Meier	 plot	 for	 progression	 free	 survival	 (>20%	 weight	
loss).	Animals	with	more	than	20%	weight	loss	were	sacrificed	(50%	survival	is	at	13.5	weeks	for	HTT	mice	
and	17.5	weeks	for	HTT/JB6	mice,	implying	a	23%	increase	in	life	span	for	the	latter).<Vaishali:	please	add	
statement	on	the	statistics	here>	
